Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.44 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.43 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.42 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.42 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | BAP1 | Q92560 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829129 | 0.98 | USP2 (0.52) | USP2ALDH1A1MEN1KMT2ANPC1 | |
| Acetic Acid SCHEMBL11101576 | 0.89 | USP2 (0.54) | USP2ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL5633033 | 0.86 | USP2 (0.58) | USP2ALDH1A1MEN1KMT2ANPC1 | |
| Trifluoroacetic Acid SCHEMBL6431095 | 0.85 | KMT2A (0.52) | USP2ALDH1A1MEN1KMT2ANPC1 | |
| Lithium Ion SCHEMBL5633232 | 0.84 | USP2 (0.57) | USP2ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL13875589 | 0.83 | USP2 (0.63) | USP2ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL8253693 | 0.83 | USP2 (0.59) | USP2ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL16372562 | 0.81 | USP2 (0.66) | USP2ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL29152989 | 0.81 | USP2 (0.66) | USP2ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL2203631 | 0.80 | USP2 (0.53) | USP2ALDH1A1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108946-A1 | LOW-TEMPERATURE CASE HARDENING OF ADDITIVE MANUFACTURED ARTICLES AND MATERIALS AND TARGETED APPLICATION OF SURFACE MODIFICATION | SWAGELOK CO (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260002244-A1 | ACTIVATION OF SELF-PASSIVATING METALS USING REAGENT COATINGS FOR LOW TEMPERATURE NITROCARBURIZATION IN THE PRESENCE OF OXYGEN-CONTAINING GAS | SWAGELOK CO (US) | 2026-01-01 | — | — | US | disclosed |
| US-12435406-B2 | Activation of self-passivating metals using reagent coatings for low temperature nitrocarburization in the presence of oxygen-containing gas | SWAGELOK COMPANY (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250297351-A1 | LASER-ASSISTED REAGENT ACTIVATION AND PROPERTY MODIFICATION OF SELF-PASSIVATING METALS | SWAGELOK COMPANY | 2025-09-25 | — | — | US | disclosed |
| CN-114929924-B | Chemical activation of self-passivating metals | 斯瓦戈洛克公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119403952-A | Laser assisted reagent activation and modification of self-passivating metals | 斯瓦戈洛克公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20250027190-A1 | CHEMICAL ACTIVATION OF SELF-PASSIVATING METALS | SWAGELOK COMPANY | 2025-01-23 | — | — | US | disclosed |
| US-12129556-B2 | Chemical activation of self-passivating metals | SWAGELOK COMPANY (US) | 2024-10-29 | — | — | US | disclosed |
| US-20240116882-A1 | NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF | TXINNO BIOSCIENCE INC. (KR) | 2024-04-11 | — | — | US | disclosed |
| EP-4330442-A1 | ACTIVATION OF SELF-PASSIVATING METALS USING REAGENT COATINGS FOR LOW TEMPERATURE NITROCARBURIZATION IN THE PRESENCE OF OXYGEN-CONTAINING GAS | Swagelok Company (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-1265870-A1 | NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES | AstraZeneca AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| US-20020115656-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-08-22 | — | — | US | disclosed |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-05-09 | — | — | US | disclosed |
| WO-2002020011-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002014315-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001066525-A1 | NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
| US-6248755-B1 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-06-19 | — | — | US | disclosed |
| EP-0029707-B1 | NOVEL PIPERIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KYOWA HAKKO KOGYO CO., LTD (JP) | 1984-02-01 | — | — | EP | disclosed |
| US-4410528-A | Hypotensive piperidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1983-10-18 | — | — | US | disclosed |
| EP-0029707-A1 | Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them | KYOWA HAKKO KOGYO CO., LTD (JP) | 1981-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115656-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | GAA 1172/4885ACHE 730/4885HTR2A 1493/4885 |
| US-20240116882-A1 | NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF | ENPP1, ENPP3, TPP1 | GAA 831/4885ACHE 427/4885HTR2A 4093/4885 |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | GAA 1172/4885ACHE 730/4885HTR2A 1493/4885 |
| US-20260002244-A1 | ACTIVATION OF SELF-PASSIVATING METALS USING REAGENT COATINGS FOR LOW TEMPERATURE NITROCARBURIZATION IN THE PRESENCE OF OXYGEN-CONTAINING GAS | NOS2, GSDMD, NOS1 | GAA 2271/4885ACHE 1357/4885HTR2A 172/4885 |
| US-20260108946-A1 | LOW-TEMPERATURE CASE HARDENING OF ADDITIVE MANUFACTURED ARTICLES AND MATERIALS AND TARGETED APPLICATION OF SURFACE MODIFICATION | NOS2, NIT2, NSUN2 | GAA 667/4885ACHE 1220/4885HTR2A 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.